Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
Beta Bionics (BBNX) Delivers +30% Revenue Growth in Q3 2026 While Losses Expand

Beta Bionics (BBNX) Delivers +30% Revenue Growth in Q3 2026 While Losses Expand

Key Takeaways

  • Beta Bionics reported third quarter 2026 net sales of $35.5 million, up 30% from $27.3 million in the prior-year period.
  • Net loss widened to $24.4 million, or $0.52 per share, from $14.2 million, or $0.33 per share, a year earlier.
  • Gross margin improved to 57.3% from 55.5%, supported by faster-growing, higher-margin pharmacy channel sales.
  • Full-year 2026 revenue guidance was updated to approximately $124 million to $126 million, from the prior range of $121 million to $126 million.
  • The company expects a full U.S. commercial launch of its Mint patch pump in the first quarter of 2027.

Why These Quarterly Results Matter

BBNX operates as a commercial-stage medical device company focused on its flagship iLet Bionic Pancreas. This system uses an FDA-cleared algorithm to automate insulin dosing for diabetes patients. As the business scales quickly yet remains unprofitable, every earnings release serves as an important check on commercial progress, channel shifts, and cash usage. I am watching the move toward the pharmacy benefit channel closely because it offers higher margins and more predictable revenue. Progress on the Mint patch pump also stands out as a key development. This quarter's numbers provide a test of whether the company can keep delivering double-digit revenue growth while it builds out its sales team and pipeline ahead of new product introductions.

Breaking Down the Reported Figures

BBNX posted third quarter 2026 net sales of $35.5 million, marking a 30% rise from $27.3 million in the same quarter last year. Revenue came in slightly above consensus estimates that clustered around $34.6 million to $35.2 million, while the net loss per share of $0.52 aligned closely with expectations.

Channel dynamics shaped the top-line outcome. Durable Medical Equipment channel sales reached $21.9 million, up 4% year over year. Pharmacy Benefit Plan channel sales hit $13.6 million, climbing 118% from the prior-year period. Gross margin rose to 57.3% from 55.5% a year earlier. The net loss totaled $24.4 million compared with $14.2 million in the year-ago quarter, driven by ongoing spending on research and development plus commercial expansion. The company closed the quarter with $373.6 million in cash, cash equivalents, and short- and long-term investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Shares of BBNX rose during the regular session on October 27, 2026, but pulled back in after-hours trading after the report. The revenue beat and continued strength in the pharmacy channel provided positives, yet the wider net loss and a slightly narrower full-year guidance range appeared to temper enthusiasm. Investors seem to be weighing the solid growth path against the costs of expanding the commercial organization before the Mint launch. The stock sits well below its 52-week high, and recent price swings indicate the market is still adjusting expectations around near-term profitability and execution.

Forward Outlook and Factors to Watch

Looking ahead, the most significant upcoming catalyst is the planned full U.S. commercial launch of the Mint tubeless patch pump in the first quarter of 2027. Management has indicated that manufacturing capacity should meet expected demand, though execution details and any remaining FDA clearance steps will require close attention.

Channel mix will remain a focal point. The fast expansion of the pharmacy benefit channel, which supports higher-margin recurring revenue, has been central to the gross margin improvement. Maintaining that momentum while adding new patient starts will influence how quickly losses begin to narrow.

Operating expense trends also deserve monitoring. The company is investing heavily in sales and marketing as well as research and development, which explains why the net loss grew even as revenue advanced. Any updates on cost management, new patient growth, and the timeline for type 2 diabetes expansion will likely receive careful scrutiny in upcoming reports. From what I see, these elements will shape the investment case in the quarters ahead.

Using AI Tools to Support My Research

I have found Tickeron’s AI Screener helpful for quickly comparing BBNX against peers in the medical device space. It lets me apply filters for technical patterns, fundamentals, and performance metrics to surface relevant ideas without manual effort. This approach keeps my workflow efficient when tracking growth stories like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BBNX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BBNX's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBNX advanced for three days, in 81 of 97 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

BBNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for BBNX moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBNX as a result. In 18 of 25 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for BBNX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 11 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BBNX moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for BBNX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.304) is normal, around the industry mean (4.142). P/E Ratio (-9.812) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.251) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. BBNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
11 Hughes
Phone
+1 949 427-7785
Employees
423
Web
https://www.betabionics.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.